Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Association of PTPN22 Polymorphism and its Correlation With Graves’ Disease Susceptibility in Polish Adult Population—A Preliminary Study
source: Molecular Genetics & Genomic Medicine
authors: Wawrusiewicz-Kurylonek N, Koper-Lenkiewicz OM, Gościk J, Myśliwiec J, Pawłowski P, Krętowski AJsummary/abstract:
Susceptibility to Graves’ disease (GD) is determined by various genetic factors; the gene encoding protein tyrosine phosphatase (PTPN22) may be one of those associated with higher risk of GD. The aim was to estimate the association of the PTPN22 gene polymorphism rs2476601:c.C>T (c.1858C>T) with the predisposition to GD within the adult north‐eastern Polish population.
PTPN22 gene polymorphism was analyzed in individuals with clinical GD history (n = 166) and healthy subjects (n = 154). The presence of different variants of the investigated gene polymorphism was estimated using the DNA Sanger sequencing method.
Patients with GD had a more frequent occurrence of the T gene allele of PTPN22 gene compared to the control group, however, it was not significant (p = 0.257). Analysis of genotype distribution showed significantly more frequent occurrence of TT homozygote in GD patients compared to control individuals (p = 0.016, OR = 9.28). Patients with ophthalmopathy had a less frequent occurrence of the T gene allele of PTPN22 gene compared to patients without ophthalmopathy, however, it was not significant (p = 0.12). Occurrence of the T gene allele of PTPN22 gene in GD manifestation in those under 40‐year old was more frequent compared to individuals over 40, but the obtained difference was also not significant (p = 0.75).
Our preliminary study suggest that PTPN22:c.1858C>T gene polymorphism may be associated with a predisposition to GD within the adult north‐eastern Polish population. The studied polymorphism of the PTPN22 gene did not significantly affect the risk of ophthalmopathy developing and disease manifestation before the age of 40.
read more full text
Dr. Scott Rivkees – “What to Expect and How To Deal with the Stress of a Child with Graves’ Diseas...https://www.youtube.com/watch?v=oC_yM7Lk...
Epidemiology, Management and Outcomes of Graves’ Disease-Real Life DataPurpose: Treatment options in Graves' d...
Treatment Options in the Young Patient With Graves’ DiseaseThe treatment options in the young patie...
Graves’ Orbitopathy as a Rare Disease in Europe: A European Group on Graves’ Orbitopathy (EUGOGO) Positi...Background: Graves' orbitopathy (GO) is...
Management of Endocrine Disease: Arguments for the Prolonged Use of Antithyroid Drugs in Children With Graves’...Graves' disease is an autoimmune disorde...
Hyperthyroidism in Children and AdolescentsWhat is the Thyroid Gland? The thyroid ...
Recurrence of Graves’ Disease is Predicted by Lower Patient Age at Initial Diagnosis: Implications for CareOne of the greatest challenges in managi...
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.